RARE * Stock Overview
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Ultragenyx Pharmaceutical Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$751.98 |
| 52 Week High | US$900.00 |
| 52 Week Low | US$594.48 |
| Beta | 0.66 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 5.32% |
| 3 Year Change | -70.19% |
| 5 Year Change | n/a |
| Change since IPO | -32.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| RARE * | MX Biotechs | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | 5.3% | 0% | 0% |
Return vs Industry: RARE * matched the MX Biotechs industry which returned 6.2% over the past year.
Return vs Market: RARE * exceeded the MX Market which returned 3.1% over the past year.
Price Volatility
| RARE * volatility | |
|---|---|
| RARE * Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: RARE * has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine RARE *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 1,276 | Emil Kakkis | www.ultragenyx.com |
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company’s products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III.
Ultragenyx Pharmaceutical Inc. Fundamentals Summary
| RARE * fundamental statistics | |
|---|---|
| Market cap | Mex$69.94b |
| Earnings (TTM) | -Mex$10.20b |
| Revenue (TTM) | Mex$7.30b |
9.6x
P/S Ratio-6.9x
P/E RatioIs RARE * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RARE * income statement (TTM) | |
|---|---|
| Revenue | US$434.25m |
| Cost of Revenue | US$119.74m |
| Gross Profit | US$314.51m |
| Other Expenses | US$921.15m |
| Earnings | -US$606.64m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.37 |
| Gross Margin | 72.43% |
| Net Profit Margin | -139.70% |
| Debt/Equity Ratio | 0% |
How did RARE * perform over the long term?
See historical performance and comparison